Neumedicines becomes member of Alliance for Biosecurity
The Alliance for Biosecurity is a collaboration among biotechnology and pharmaceutical companies that work in the public interest to improve prevention and treatment of biological threats, diseases and syndromes that pose global security challenges. Neumedicines said its goals were in alignment with the mission of the alliance.
"Our company's goals are aligned with those of the alliance's," Lena Basile, the president and CEO of Neumedicines, said. "We are striving to promote a stronger, more effective partnership between government, the biopharmaceutical industry and other stakeholders with the aim of advancing the development of critically needed medical countermeasures. We were delighted to be invited to join the alliance, where we are currently the only member focused on achieving and sustaining a medical countermeasure against radiation."
Neumedicines said the Alliance for Biosecurity is seeking to develop sound proposals for public policy that would strengthen U.S. efforts to quickly develop, produce, stockpile and distribute medical countermeasures.
Neumedicines received more than $49 million from the Biomedical Advanced Research and Development Authority to support the development of HemaMax, a human interleukin-12-based radiation countermeasure. HemaMax is meant to treat hematopoietic syndrome of acute radiation sickness.
In previous studies, Neumedicines found that HemaMax was able to significantly increase survival in non-human primates after exposure to lethal amounts of radiation. First-in-human and Phase 1b studies found that HemaMax was safe in healthy, human volunteers.